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INTRODUCTION
Cisplatin-based systemic chemotherapy is the standard approach for patients with inoperably advanced or metastatic urothelial carcinoma (UC). Combined chemotherapy of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), which was developed about 25 years ago, is an effective and frequently used modality for these life-threatening diseases. [1] [2] [3] The good performance of MVAC was demonstrated in the initial randomized trial. Advanced UC patients were randomized to receive MVAC regimen or cisplatin alone, and the overall survival of the groups was 12.5 months and 8.2 months, respectively.
3) However, most UC patients will subsequently develop regional progression or distant metastases. The prognosis of patients with advanced or metastatic UC remains poor, with a median survival of approximately 12 months. 2) External beam radiation therapy (EBRT) is a bladdersparing treatment that has been performed for about 30 years. The local recurrence rate after EBRT alone was up to 70%, with 5-year overall survival rates from 20% to 40%. 4, 5) Interestingly, preclinical studies with bladder cancer animal models have demonstrated synergistic cytotoxicity when cisplatin was combined with concurrent EBRT. 6) To overcome biologically aggressive advanced or metastatic UC, several investigators have recently explored the use of combined chemotherapy with radiation in an attempt to improve the results of EBRT alone.
Multimodal treatment has become a standard of care for other kinds of malignancy. Combined chemotherapy with radiation for the treatment of advanced bladder cancer remains questionable, including whether this would eradicate local disease, eliminate potential micrometastases, and maintain the best quality of life possible without compromising survival. In clinical trials including cisplatin-based chemotherapy and radiation for bladder cancer, complete response (CR) was approximately 70% and 3-to 5-year overall survival was 35-83%. [7] [8] [9] [10] [11] [12] [13] [14] In addition, overall survival was similar to that of radical surgery in bladder cancer patients. However, these previous clinical trials mainly consisted of patients with organ-confined diseases. The objective of this study was to determine the tolerability of combined MVAC with radiation and to access the efficacy in patient with locally advanced or metastatic bladder cancer.
MATERIALS AND METHODS

Patients
From December 2000 to November 2010, 183 patients with advanced or metastatic bladder cancer were treated. All patients were measurable or assessable and were histologically or cytologically proven to have locally advanced (T2-T4, N1 or N2) or metastatic (M1) UC of the bladder. One hundred fifty three patients (83.6%) were excluded from this study: 74 patients (40.4%) received radical cystectomy, 69 patients (37.7%) received systemic chemotherapy alone because of multiple sites and metastases, and 10 patients (5.5%) received ERBT alone because of elderly and renal dysfunction. Thirty eligible patients (16.4%) received concurrent chemoradiotherapy using MVAC treatment. Locally advanced patients had inoperable advanced diseases or refused the radical cystectomy. Only 2 patients who received chemotherapy and EBRT to the advanced bladder cancer had one site bone metastasis. For inclusion in this study, patients were required to have an Eastern Cooperative Oncology Group performance status (PS) of 2 or lower per World Health Organization criteria, adequate bone marrow reserve (white blood cell [WBC] count higher than 3500/μL, platelet count higher than 100,000/μL, and hemoglobin higher than 10 g/dl); hepatic function (serum bilirubin 1.5 mg/dl or less), renal function (serum creatinine 1.5 mg/dl or measured creatinine clearance of at least 60 ml/min), and an estimated life expectancy of at least 12 weeks. Patients with nonmalignant systematic disease that precluded them from receiving therapy, including active infection, any clinically significant cardiac arrhythmia, or congestive heart failure, were not eligible. Patients with central nerve system metastases, second primary malignant lesions, or clinically significant pleural effusions or ascites or who used any investigational agent 1 month before enrollment were not eligible. Written informed consent was obtained from all patients before they entered this clinical trial. The study was approved by the institutional chemotherapy review board at Kitasato University Hospital and conducted in accordance with the Declaration of Helsinki.
Treatment schedule
All patients received intravenous methotrexate, 30 mg/m 2 on days 1, 15, and 22; cisplatin or nedaplatin, 70 mg/m 2 on day 2; doxorubicin, 70 mg/m 2 on day 2; and vinblastine, 3 mg/m 2 on days 2, 15, and 22. After receiving one cycle of chemotherapy, all patients received EBRT with a half dose of MVAC treatment followed by two more cycles of chemotherapy. Nineteen patients received chemotherapy with nedaplatin rather than cisplatin because of creatinine clearance of less than 60 ml/min. On days 15 and 22 of each cycle, methotrexate and vinblastine were given if the patient had a WBC count higher than 3000/μL and platelet count higher than 100,000/μL; otherwise methotrexate and vinblastine were omitted. Missed doses were not given, which could result in a 28-day cycle. On the first day of each course, full doses of methotrexate were administered if the WBC count was higher than 3000/μL and platelet count was higher than 100,000/μL. If counts were lower than these levels, treatment was delayed for 1 week and administered at the previous dose levels if the counts had increased to higher than these levels.
Radiation therapy was performed if the WBC count was higher than 1500/μL or platelet count was higher than 25,000/μL. A standard fractionation with daily dose of 1.8-2.0 Gy was used, with median total dose of 53 Gy (range, 45-60 Gy) over 5-6 weeks. Generally, the bladder tumor, bladder, and regional lymph nodes were treated with a fourfield box technique.
Supportive care could include blood transfusion, antiemetics, and analgesics. Prophylactic use of growth factors was not performed. Further local therapy, including other chemotherapy or local radiation therapy, was allowed for patients with locally advanced disease after their responses to this regimen were assessed.
Treatment evaluation
During treatment, blood counts and serum chemistries were carried out weekly, and creatinine clearance was calculated before chemotherapy. Tumors were assessed by computerized tomography or magnetic resonance imaging every two cycles, and responses were determined at least 4 weeks after administration.
Based on patient medical records, overall survival was measured until death and time to failure was measured until discontinuation of treatment, death, or progression. Patients were assigned a response category according to the Response Evaluation Criteria in Solid Tumors. Adverse events were monitored according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
Statistical analyses
For statistical analysis, PS (0 or 1 versus 2), response (CR versus non-CR), number of chemotherapy cycles (four cycles versus two or three cycles), lymph node status (N0 versus N1 or N2), tumor pathologic stage (pT2 or pT3 versus pT4), irradiation dose (60 Gy versus < 60 Gy) were evaluated as dichotomized variables. Overall survival rate and response duration were calculated from the first day of chemotherapy treatment until the date of progression or death. Overall survival and progression-free survival were analyzed with the Kaplan-Meier methods. Multivariate survival analyses were performed with the Cox proportional hazards regression model, controlling for PS, response, number of chemotherapy cycles, lymph node metastases, pathologic stage, and irradiation dose. All analyses were performed with StatView, version 5.0 (SAS Institute, Cary, NC, USA), and P < 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
The clinical characteristics of all patients are listed in Table 1 . This study demonstrated that radiotherapy combined with MVAC treatment produces an 80% response rate with a manageable toxicity profile for locally advanced or metastatic UC patients. CR was confirmed in 13 patients (43%) and 11 patients (37%) showed partial response. The median overall survival and progression-free survival were 25.5 months and 12.8 months, respectively (Fig. 1A, B) . As shown in Fig. 1C-F , the median survival time of 13 patients with CR was 37.1 months (range, 6.9-38.0 months). According to multivariate Cox proportional hazards regression analysis, good PS, CR, and four cycles of MVAC were significant predictors of progression-free survival (P = 0.025, 0.001, and 0.005, respectively). Moreover, patients with a negative lymph node status had a tendency of better progression-free survival, although this was not significant (P = 0.051) ( Table 2 ). The hematological and nonhematological toxicities in the 30 patients are listed in Table 3 . Myelosuppresion was the most common toxicity. In the nonhematological toxicities, grade 3 hematuria occurred in four patients (13%). Three patients (10%) had bleeding from the bladder cancer, and one patient (3%) had hemorrhagic radiation cystitis. The median overall treatment time of radiation therapy was 40 days (range, 35 -47 days), and there were no brakes or delay cases due to concurrent MVAC chemotherapy. There were no treatment-related deaths in this study.
In the Radiation Therapy Oncology Group (RTOG) 89-03 study, 15) 123 patients with T2-T4a bladder cancer were randomly assigned to receive either two cycles of chemotherapy followed by 64.8 Gy of EBRT with concomitant use of cisplatin or only chemo-radiation without prior chemotherapy. There were no significant differences in terms of 5-year overall survival, rates of distant metastasis, and survival with a functioning bladder in both arms. However, combining chemotherapy and radiotherapy was based on several assumptions. First, autopsy data show that micrometastases are often present in patients with invasive bladder cancer. One study examined autopsies from 367 individuals with muscle-invasive bladder cancer (pT2-pT4) and identified distant metastases in 68%; the frequency of metastases increased with tumor stage (pT2, 36%; pT3a, 45%; pT3b, 69%; pT4, 79%).
16) The rationale of induction chemotherapy is to treat initially present micrometastasis. 17) In addition, systemic chemotherapy is tolerated better before the irradiation of cancer lesions than after local therapy. 8, 15) Furthermore chemotherapy coupled with radiation may add the therapeutic effect of reducing the rate of distant failures. Second, drug resistance to cytotoxic agents may be related to spontaneous mutations in cancer cells, which occurs more often in tumors of greater mass. 18) Third, hypoxic cells exist in solid tumors with poor vascularity and are likely to be resistant to the treatment, especially to radiation. However, these cells may be more sensitive to the combined effects of cytotoxic agents and radiotherapy. 19) Reoxygenation in hypoxic tumor cells, which increases the radiosensitivity, may occur after induction chemotherapy and result in tumor shrinkage. Fourth, radiotherapy can induce vascular sclerosis, which causes reduced access of chemotherapy agents to tumor sites. 20) The administration of chemotherapy before post-radiation sclerosis could increase chemoresponsiveness. Finally, certain chemotherapy drugs, such as 5-fluorouracil, cisplatin, gemcitabine, and paclitaxel, have been reported to react as radiosensitizers, which render malignant tissues more sensitive to radiation. 21) According to this rationale, we conducted chemoradiotherapy in patients with locally advanced or metastatic bladder cancers. All patients received induction chemotherapy (one cycle of full-dose MVAC treatment) followed by chemoradiotherapy (EBRT concurrently combined with a half dose of MVAC treatment). The therapeutic modality in this study showed a survival benefit, particularly in locally advanced or metastatic bladder cancers, as compared to previous reports. 22, 23) According to multivariate analysis, good PS, CR, and four cycles of MVAC were significant predictors of progressionfree survival. Several studies have reported on the prognostic factors in patients with invasive bladder cancer who were treated with chemoradiotherapy. Coppin et al. 12) reported that low clinical staging (T2-T3a versus T3b-T4) was the independent prognostic factor of overall survival and progression-free survival. Rodel et al. 9) showed that low clinical stage and complete transurethral resection had the strongest impact on overall survival. In addition, Arias et al. 24) demonstrated that the significant factors for overall survival were T2 stage and absence of hydronephrosis. Thus, several studies showed that low clinical stage was a significant factor for survival. However, clinical stage was not a significant predictor in this study. Although this study contained 25 patients (83%) who had locally advanced or metastatic disease, this patient set could be more reliable for treatment in real clinical scenarios.
The clinical applicability of this chemoradiotherapy is supported by the outpatient administration and a tolerable toxicity profile in previously treated patients. In the RTOG 89-03 study, 15) grade 3 or higher febrile neutropenia during the two cycles of methotrexate, cisplatin, and vinblastine was observed in 23% of patients, and lethal complication from neutropenia and sepsis occurred in three patients. Arias et al. 24) reported that the severe adverse events following MVAC included alopecia (30%), leucopenia (16%), vomiting (12%), and thrombocytopenia (4%), while concomitant chemoradiotherapy showed severe cystitis (12%), diarrhea (4%), and leucopenia (4%). In this study no life-threatening complication was seen. Although patients with grade 3-4 neutropenia were frequently seen, these patients were safely treated with granulocyte-colony stimulating factor and none of them had severe infections. In addition, no severe hematologic toxicities were found in patients treated with a half dose of MVAC chemotherapy with radiation. With regard to nonhematological toxicities, only one patient experienced hemorrhagic radiation cystitis 1 year after radiotherapy.
One limitation of this study is that efficacy and tolerability data for this chemoradiotherapy were evaluated retrospectively and not in a randomized trial. Our sample size was too small for analysis, and we could not distribute a quality-oflife questionnaire for chemoradiotherapy. Although there was no significant predictor in terms of overall survival according to multivariate analysis, 13 patients (43%) who were treated with this chemoradiotherapy showed CR and 24 patients (80%) had major responses. In addition, they had significantly prolonged survival compared to nonresponding patients. Therefore, we conclude that this regimen is effective and safe for patients with advanced or metastatic bladder cancer.
Concurrent chemoradiotherapy with MVAC treatment is a favorable therapeutic option for patients with advanced or metastatic bladder cancer. Given the safety and benefit profile seen in this study, appropriate case selection is warranted in the future. 
